Evidence map›Paper›PMID 25619867›Full record

ArticleACS nano2015

Inhibition of the enhancement of infection of human immunodeficiency virus by semen-derived enhancer of virus infection using amyloid-targeting polymeric nanoparticles.

Daniel A Sheik, Lauren Brooks, Kristen Frantzen, Stephen Dewhurst, Jerry Yang

Abstract read
In one paragraph

Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Structure, function and antagonism of semen amyloids.Chemical communications (Cambridge, England) · 2018
    Review
  7. Semen-derived amyloidogenic peptides-Key players of HIV infection.Protein science : a publication of the Protein Society · 2018
    Review
  8. Natural product-based nanomedicine: recent advances and issues.International journal of nanomedicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Daniel A Sheik *Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla CA 92093-0358, United States.
Lauren Brooks *Department of Microbiology and Immunology, University of Rochester, Rochester, New York 14642, United States.
Kristen FrantzenDepartment of Microbiology and Immunology, University of Rochester, Rochester, New York 14642, United States.
Stephen DewhurstDepartment of Microbiology and Immunology, University of Rochester, Rochester, New York 14642, United States.
Jerry YangDepartment of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla CA 92093-0358, United States.
University of Rochester · USUniversity of California, San Diego · US

Funding

Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Training in Cellular, Biochemical and Molecular SciencesT32GM068411 · NIGMS · UNIVERSITY OF ROCHESTER · PI MAQUAT, LYNNE E · 2005 to 2019
$3.9M
The Semen Enhancer of HIV Infection as a Novel Microbicide TargetR33AI094511 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2013 to 2015
$1.1M
The University of Rochester Clinical and Translational Science InstituteTL1TR000096 · NCATS · UNIVERSITY OF ROCHESTER · PI BENNETT, NANCY M, KIEBURTZ, KARL D. · 2012 to 2015
$930k
The Semen Enhancer of HIV Infection as a Novel Microbicide TargetR21AI094511 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2011 to 2012
$434k
Acquisition of a High Resolution TOF Mass SpectrometerS10RR025636 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MOLINSKI, TADEUSZ F · 2010 to 2010
$305k
NCRR NIH HHS S10 RR025636NCRR NIH HHS S10RR25636NIAID NIH HHS P30 AI078498NIAID NIH HHS P30AI078498NIAID NIH HHS R21 AI094511NIAID NIH HHS R21AI094511NIAID NIH HHS R33 AI094511NIAID NIH HHS R33AI094511NIGMS NIH HHS T32 GM068411
6 · The paper itself

Abstract

The semen-derived enhancer of virus infection (SEVI) is a natural amyloid material that has been shown to substantially increase viral attachment and infectivity of HIV in cells. We previously reported that synthetic monomeric and oligomeric amyloid-targeting molecules could form protein-resistive coatings on SEVI and inhibit SEVI- and semen-mediated enhancement of HIV infectivity. While oligomeric amyloid-binding compounds showed substantial improvement in apparent binding to SEVI compared to monomeric compounds, we observed only a modest correlation between apparent binding to SEVI and activity for reducing SEVI-mediated HIV infection. Here, we synthesized amyloid-binding polyacrylate-based polymers and polymeric nanoparticles of comparable size to HIV virus particles (∼150 nm) to assess the effect of sterics on the inhibition of SEVI-mediated enhancement of HIV infectivity. We show that these polymeric materials exhibit excellent capability to reduce SEVI-mediated enhancement of HIV infection, with the nanoparticles exhibiting the greatest activity (IC50 value of ∼4 μg/mL, or 59 nM based on polymer) of any SEVI-neutralizing agent reported to date. The results support that the improved activity of these nanomaterials is likely due to their increased size (diameters = 80-200 nm) compared to amyloid-targeting small molecules and that steric interactions may play as important a role as binding affinity in inhibiting viral infection mediated by SEVI amyloids. In contrast to the previously reported SEVI-neutralizing, amyloid-targeting molecules (which required concentrations at least 100-fold above the Kd to observe activity), the approximate 1:1 ratio of apparent Kd to IC50 for activity of these polymeric materials suggests the majority of polymer molecules that are bound to SEVI contribute to the inhibition of HIV infectivity enhanced by SEVI. Such size-related effects on physical inhibition of protein-protein interactions may open further opportunities for the use of targeted nanomaterials in disease intervention.

Indexed as

NanoparticlesProtein MultimerizationAcrylic ResinsAmyloidBenzothiazolesCell Line, TumorDrug DesignHIVHumansModels, MolecularProtein Structure, SecondaryThermodynamicsVirus AttachmentAcrylic ResinsAmyloidbenzothiazoleBenzothiazolescarbopol 940acrylateHIVnanoparticlespolymerSEVIsteric inhibition

Identifiers

PMID25619867
PMCPMC4426188
OpenAlexW2317902761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.